IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

01. Dezember 18:02 Bayer investiert in Nachhaltigkeit

01. Dezember 18:37 Shop Apotheke und Zur Rose? Beide haben noch Potenzial

01. Dezember 18:50 Bitcoin: Schlägt jetzt die Stunde der Bullen?

01. Dezember 19:00 Gold: Das klingt nicht gut

01. Dezember 19:48 Die OPEC tagt, TotalEnergies steigt

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021